🇺🇸 FDA
Patent

US 11974980

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

granted A61KA61K31/343A61K31/352

Quick answer

US patent 11974980 (In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors) held by Provectus Pharmatech, Inc. expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Provectus Pharmatech, Inc.
Grant date
Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/343, A61K31/352, A61K31/365, A61K31/4745